Over the past decades, our molecular understanding of acute myeloid leukemia (AML) pathogenesis dramatically increased, thanks also to the advent of next-generation sequencing (NGS) technologies. Many of these findings, however, have not yet translated into new prognostic markers or rationales for treatments. We now know that AML is a highly heterogeneous disease characterized by a very low mutational burden. Interestingly, the few mutations identified mainly reside in epigenetic regulators, which shape and define leukemic cell identity. In the light of these discoveries and given the increasing number of drugs targeting epigenetic regulators in clinical development and testing, great interest is emerging for the use of small molecules targeting leukemia epigenome. Together with their effects on leukemia cell-intrinsic properties, such as proliferation and survival, epigenetic drugs may affect the way leukemic cells communicate with the surrounding components of the tumor and immune microenvironment. Here, we review current knowledge on alterations in the AML epigenetic landscape and discuss the promises of epigenetic therapies for AML treatment. Finally, we summarize emerging molecular studies elucidating how epigenetic rewiring in cancer cells may as well exert immune-modulatory functions, boost the immune system, and potentially contribute to better patient outcomes.

Gambacorta, V., Gnani, D., Vago, L., Di Micco, R. (2019). Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 7 [10.3389/fcell.2019.00207].

Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects

Gambacorta, V;
2019

Abstract

Over the past decades, our molecular understanding of acute myeloid leukemia (AML) pathogenesis dramatically increased, thanks also to the advent of next-generation sequencing (NGS) technologies. Many of these findings, however, have not yet translated into new prognostic markers or rationales for treatments. We now know that AML is a highly heterogeneous disease characterized by a very low mutational burden. Interestingly, the few mutations identified mainly reside in epigenetic regulators, which shape and define leukemic cell identity. In the light of these discoveries and given the increasing number of drugs targeting epigenetic regulators in clinical development and testing, great interest is emerging for the use of small molecules targeting leukemia epigenome. Together with their effects on leukemia cell-intrinsic properties, such as proliferation and survival, epigenetic drugs may affect the way leukemic cells communicate with the surrounding components of the tumor and immune microenvironment. Here, we review current knowledge on alterations in the AML epigenetic landscape and discuss the promises of epigenetic therapies for AML treatment. Finally, we summarize emerging molecular studies elucidating how epigenetic rewiring in cancer cells may as well exert immune-modulatory functions, boost the immune system, and potentially contribute to better patient outcomes.
Articolo in rivista - Review Essay
acute myeloid leukemia; chromatin; epigenetics; immune activation; therapy;
AML, Epigenetics, Epigenetic Therapy, Immune system
English
2019
7
207
none
Gambacorta, V., Gnani, D., Vago, L., Di Micco, R. (2019). Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 7 [10.3389/fcell.2019.00207].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/246512
Citazioni
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 26
Social impact